NEUROCRINE BIOSCIENCES INC Operating Lease Right-of-Use Assets
NEUROCRINE BIOSCIENCES INC (NBIX) had Operating Lease Right-of-Use Assets of $448.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-07-31
- 2026-06-30: Operating Lease, Right-of-Use Asset $448.00M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $447.10M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $455.40M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $468.90M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $448.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $447.10M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $455.40M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $468.90M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $492.30M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $502.20M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $509.40M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $257.30M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $262.90M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $270.80M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $276.50M 10-K · filed 2025-02-10 | |
| 2023-09-30 | $80.80M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $83.50M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $84.40M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $87.00M 10-K · filed 2024-02-09 | |
| 2022-09-30 | $89.60M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $92.20M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $94.70M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $97.20M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $97.90M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $100.30M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $97.00M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $82.80M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $71.00M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $72.10M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $73.30M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $74.30M 10-K · filed 2021-02-05 | $74.36M 10-K · filed 2020-02-07 |
| 2019-09-30 | $61.99M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $49.09M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $49.30M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |